- China starts formal legal proceedings against disgraced senior politic
- Venezuela socialists winning local vote, Maduro joyous
- Bitcoin jumps after futures trading begins
- Six New Street Fighter 5 Characters Revealed For Season 3 Of Content
- China, Taiwan spar over Chinese diplomat's invasion threat
- Israeli army destroys tunnel from Gaza
- With foes abstaining, Venezuela mayoral contests to boost socialists
- Futures trading arrives for bitcoin
- Global arms sales rise for the first time in 5 years
- LawBreakers Boss Leaves To Join Epic For A "Secret Project"
- Pro tips: Shooting Hong Kong like a street photographer
- With foes abstaining, Venezuela mayoral contests look set to boost Soc
- Rebel architecture: In praise of Britain's postmodern oddities
- 'Star Wars' fans, box office analysts brace themselves for 'The Last Jedi'
- PUBG Xbox One Exact Release Timing Revealed, Controller Setup Detailed
- With foes absent, Venezuela local vote to boost socialists
- Haley on Trump accusers: 'We should all be willing to listen to them'
- May hails new optimism in Brexit talks after deal
- China's top paper says Australian media reports are racist
- Syrian army and Iranian-backed militias push towards Idlib province
Roche's Foundation Medicine wins FDA blessing for new cancer test
ZURICH (Reuters) - Roche on Monday said its Foundation Medicine unit won U.S. Food and Drug Administration (FDA) approval for a test to help doctors understand the genetic profile of patients’ tumors and guide them to effective therapies.
Roche, which owns 58 percent of Foundation, is hoping to use the FoundationOne CDx assay to personalize cancer care, where treatment is better tailored to the specific molecular characteristics of each patient’s disease.
Our Standards:The Thomson Reuters Trust Principles.